{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:39:17Z","timestamp":1787647157386,"version":"build-2736575974"},"reference-count":76,"publisher":"Scientific Scholar","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec>\n            <jats:title>Background &amp; objectives:<\/jats:title>\n            <jats:p>Neonates present a special subgroup of population in whom optimization of antimicrobial dosing can be particularly challenging. Gram-negative infections are common in neonates, and inpatient treatment along with critical care is needed for the management of these infections. Dosing recommendations are often extrapolated from evidence generated in older patient populations. This systematic review was done to identify the knowledge gaps in the pharmacokinetics-pharmacodynamics (PK-PD)-based optimized dosing schedule for parenteral antimicrobials for Gram-negative neonatal infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Relevant research questions were identified. An extensive electronic and manual search methodology was used. Potentially eligible articles were screened for eligibility. The relevant data were extracted independently in a pre-specified data extraction form. Pooling of data was planned.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 340 records screened, 24 studies were included for data extraction and incorporation in the review [carbapenems - imipenem and meropenem (n=7); aminoglycosides - amikacin and gentamicin (n=9); piperacillin-tazobactam (n=2); quinolones (n=2); third- and fourth-generation cephalosporins (n=4) and colistin nil]. For each of the drug categories, the information for all the questions that the review sought to answer was incomplete. There was a wide variability in the covariates assessed, and pooling of results could not be undertaken.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interpretation &amp; conclusions:<\/jats:title>\n            <jats:p>There is a wide knowledge gap for determining the doses of antimicrobials used for Gram-negative infections in neonates. A different profile of newborns in the developing countries could affect the disposition of antimicrobials for Gram negative infections, necessitating the generation of PK-PD data of antimicrobials in neonates from developing countries. Further, guidelines for treatment of neonatal conditions may incorporate the evidence-based PK-PD-guided dosing regimens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_723_15","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:12:48Z","timestamp":1734635568000},"page":"299-316","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates"],"prefix":"10.25259","volume":"145","author":[{"given":"Nusrat","family":"Shafiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilima A.","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-6-20241212","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/archdischild-2013-303721","article-title":"Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling","volume":"99","author":"Admiraal","year":"2014","journal-title":"Arch Dis Child"},{"key":"R2-6-20241212","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pharmthera.2008.02.005","article-title":"The ontogeny of drug metabolism enzymes and implications for adverse drug events","volume":"118","author":"Hines","year":"2008","journal-title":"Pharmacol Ther"},{"key":"R3-6-20241212","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/BF02002914","article-title":"Serum creatinine concentration, urinary creatinine excretion and creatinine clearance during the first 9 weeks in preterm infants with a birth weight below 1500 g","volume":"155","author":"Sonntag","year":"1996","journal-title":"Eur J Pediatr"},{"key":"R4-6-20241212","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003246-199702000-00013","article-title":"Gentamicin pharmacokinetics in neonates with patent ductus arteriosus","volume":"25","author":"Williams","year":"1997","journal-title":"Crit Care Med"},{"key":"R5-6-20241212","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.jp.7210985","article-title":"Gentamicin pharmacokinetics in term newborn infants receiving high-frequency oscillatory ventilation or conventional mechanical ventilation: A case-controlled study","volume":"23","author":"Bhatt-Mehta","year":"2003","journal-title":"J Perinatol"},{"key":"R6-6-20241212","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/00003088-200645070-00005","article-title":"Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates","volume":"45","author":"Peters","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R7-6-20241212","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.siny.2012.10.002","article-title":"Effect of hypothermia and extracorporeal life support on drug disposition in neonates","volume":"18","author":"Wildschut","year":"2013","journal-title":"Semin Fetal Neonatal Med"},{"key":"R8-6-20241212","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/INF.0000000000000549","article-title":"Etiology of bacteremia in young infants in six countries","volume":"34","author":"Hamer","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R9-6-20241212","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1128\/AAC.34.6.1172","article-title":"Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life","volume":"34","author":"Reed","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-6-20241212","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/INF.0b013e31829b5880","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children","volume":"32","author":"Yoshizawa","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R11-6-20241212","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/AAC.01149-05","article-title":"Prospective determination of plasma imipenem concentrations in critically ill children","volume":"50","author":"Giannoni","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-6-20241212","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/INF.0b013e31822e8b0b","article-title":"Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections","volume":"30","author":"Smith","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R13-6-20241212","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/INF.0b013e318170f8d2","article-title":"Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate","volume":"27","author":"Bradley","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R14-6-20241212","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn","volume":"53","author":"van den Anker","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-6-20241212","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1128\/AAC.00655-12","article-title":"Short versus long infusion of meropenem in very-low-birth-weight neonates","volume":"56","author":"Padari","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-6-20241212","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00228-009-0637-4","article-title":"Individualised dosing of amikacin in neonates: A pharmacokinetic\/pharmacodynamic analysis","volume":"65","author":"Sherwin","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R17-6-20241212","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/FTD.0b013e31806db3f5","article-title":"Renal drug clearance in preterm neonates: Relation to prenatal growth","volume":"29","author":"Allegaert","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R18-6-20241212","first-page":"139","article-title":"Limited predictability of amikacin clearance in extreme premature neonates at birth","volume":"61","author":"Allegaert","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R19-6-20241212","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000047133","article-title":"Once-a-day individualized amikacin dosing for suspected infection at birth based on population pharmacokinetic models","volume":"80","author":"Labaune","year":"2001","journal-title":"Biol Neonate"},{"key":"R20-6-20241212","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jpeds.2008.04.060","article-title":"Observational trial of a 48-hour gentamicin dosing regimen derived from Monte Carlo simulations in infants born at less than 28 weeks'gestation","volume":"153","author":"Thingvoll","year":"2008","journal-title":"J Pediatr"},{"key":"R21-6-20241212","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00006454-200203000-00014","article-title":"Comparison of two gentamicin dosing schedules in very low birth weight infants","volume":"21","author":"Rastogi","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"R22-6-20241212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000457735","article-title":"Effect of patent ductus arteriosus on gentamicin pharmacokinetics in very low birth weight (less than 1,500 g) babies","volume":"10","author":"Watterberg","year":"1987","journal-title":"Dev Pharmacol Ther"},{"key":"R23-6-20241212","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1023\/A:1012490704731","article-title":"Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus","volume":"23","author":"Touw","year":"2001","journal-title":"Pharm World Sci"},{"key":"R24-6-20241212","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00228-012-1413-4","article-title":"Population pharmacokinetics of piperacillin\/tazobactam in neonates and young infants","volume":"69","author":"Li","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R25-6-20241212","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/FTD.0b013e3182587665","article-title":"Population pharmacokinetics of piperacillin using scavenged samples from preterm infants","volume":"34","author":"Cohen-Wolkowiez","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R26-6-20241212","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1128\/AAC.03568-14","article-title":"Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age","volume":"58","author":"Zhao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-6-20241212","first-page":"1001","article-title":"Multiple dose pharmacokinetics of ciprofloxacin in preterm babies","volume":"41","author":"Aggarwal","year":"2004","journal-title":"Indian Pediatr"},{"key":"R28-6-20241212","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/BF01650725","article-title":"Cefotaxime pharmacokinetics and treatment of meningitis in neonates","volume":"17","author":"Jacobs","year":"1989","journal-title":"Infection"},{"key":"R29-6-20241212","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1128\/AAC.39.9.2048","article-title":"Once-daily versus twice-daily administration of ceftazidime in the preterm infant","volume":"39","author":"van den Anker","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-6-20241212","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1128\/AAC.49.7.2760-2766.2005","article-title":"Population pharmacokinetics of cefepime in the neonate","volume":"49","author":"Capparelli","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"R31-6-20241212","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2710.2008.00913.x","article-title":"Population pharmacokinetics of cefepime in neonates with severe nosocomial infections","volume":"33","author":"Lima-Rogel","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"R32-6-20241212","first-page":"485","article-title":"Clinical and pharmacokinetic study of imipenem\/cilastatin in children and newborn infants","volume":"37","author":"B\u00e9gu\u00e9","year":"1989","journal-title":"Pathol Biol (Paris"},{"key":"R33-6-20241212","first-page":"1692","article-title":"Bacteriological and clinical evaluations of imipenem\/cilastatin sodium in neonates and premature infants","volume":"41","author":"Sunakawa","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R34-6-20241212","first-page":"1650","article-title":"Clinical and pharmacokinetic evaluation of imipenem\/cilastatin sodium in neonates and young infants","volume":"41","author":"Sakata","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R35-6-20241212","first-page":"1671","article-title":"Pharmacokinetic and clinical studies on imipenem\/cilastatin sodium in neonates and premature infants","volume":"41","author":"Toyonaga","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R36-6-20241212","first-page":"1721","article-title":"Pharmacokinetics and clinical evaluation of imipenem\/cilastatin sodium in pediatric surgery","volume":"41","author":"Yura","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R37-6-20241212","first-page":"1715","article-title":"Evaluation of imipenem\/cilastatin sodium in neonatal infections","volume":"41","author":"Okura","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R38-6-20241212","first-page":"953","article-title":"Pharmacokinetic and clinical evaluation of imipenem\/cilastatin sodium in neonates and premature infants. A study of imipenem\/cilastatin sodium by a perinatal co-research group","volume":"42","author":"Fujii","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R39-6-20241212","first-page":"1657","article-title":"Pharmacokinetic and clinical studies with imipenem\/cilastatin sodium in neonates","volume":"41","author":"Sato","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R40-6-20241212","first-page":"1704","article-title":"Pharmacokinetics and clinical efficacy of imipenem\/cilastatin sodium in neonates","volume":"41","author":"Azagami","year":"1988","journal-title":"Jpn J Antibiot"},{"key":"R41-6-20241212","first-page":"1102","article-title":"Pharmacokinetic and clinical evaluations of imipenem\/cilastatin sodium in neonates and premature infants","volume":"42","author":"Motohiro","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R42-6-20241212","first-page":"1087","article-title":"Pharmacokinetic, bacteriological and clinical studies on imipenem\/cilastatin sodium in neonates","volume":"42","author":"Iwai","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R43-6-20241212","first-page":"1077","article-title":"Pharmacokinetic, bacteriological and clinical studies on imipenem\/cilastatin sodium in neonates","volume":"42","author":"Hashira","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R44-6-20241212","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1128\/AAC.27.4.431","article-title":"Pharmacokinetics of imipenem-cilastatin in neonates","volume":"27","author":"Freij","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-6-20241212","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/AAC.27.4.511","article-title":"Single-dose pharmacokinetics of imipenem-cilastatin in neonates","volume":"27","author":"Gruber","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-6-20241212","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/archdischild-2014-306873","article-title":"Therapeutic guidelines for prescribing antibiotics in neonates should be evidence based: A French National Survey","volume":"100","author":"Lerouz","year":"2015","journal-title":"Arch Dis Child"},{"key":"R47-6-20241212","first-page":"299","article-title":"Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem\/cilastatin","volume":"27","author":"B\u00f6swald","year":"1999","journal-title":"Infection"},{"key":"R48-6-20241212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.TA.0000056164.26493.28","article-title":"Imipenem levels are not predicTable in the critically ill patient","volume":"56","author":"Belzberg","year":"2004","journal-title":"J Trauma"},{"key":"R49-6-20241212","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/jac\/18.Supplement_E.121","article-title":"The effect of imipenem\/cilastatin on the aerobic faecal flora of children","volume":"18","author":"Borderon","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"R50-6-20241212","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/00007691-200106000-00003","article-title":"Pharmacokinetics of meropenem in preterm neonates","volume":"23","author":"van Enk","year":"2001","journal-title":"Ther Drug Monit"},{"key":"R51-6-20241212","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jpba.2006.02.017","article-title":"Stability and degradation kinetics of meropenem in powder for injection and reconstituted sample","volume":"41","author":"Mendez","year":"2006","journal-title":"J Pharm Biomed Anal"},{"key":"R52-6-20241212","first-page":"CD005091","article-title":"One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates","volume":"11","author":"Rao","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"R53-6-20241212","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1128\/AAC.46.5.1381-1387.2002","article-title":"Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children","volume":"46","author":"Tr\u00e9luyer","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R54-6-20241212","first-page":"817","article-title":"Long term circulatory and renal consequences of intrauterine growth restriction","volume":"94","author":"Simeonai","year":"2005","journal-title":"Acta Paediatr"},{"key":"R55-6-20241212","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/jcph.190","article-title":"Impact of small-for-gestational age (SGA) status on gentamicin pharmacokinetics in neonates","volume":"54","author":"Lulic-Botica","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R56-6-20241212","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1651-2227.2004.tb02961.x","article-title":"Evaluation of an amikacin loading dose for nosocomial infections in very low birthweight infants","volume":"93","author":"Berger","year":"2004","journal-title":"Acta Paediatr"},{"key":"R57-6-20241212","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/jac\/dkv052","article-title":"Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates","volume":"70","author":"Valitalo","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R58-6-20241212","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/AAC.38.12.2817","article-title":"Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children","volume":"38","author":"Reed","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"R59-6-20241212","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00228-012-1415-2","article-title":"Wide intra- and inter-country variability in drug use and dosage in very-low-birth-weight newborns with severe infections","volume":"69","author":"Pandolfini","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R60-6-20241212","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1136\/adc.64.10_Spec_No.1388","article-title":"Ciprofloxacin in neonatal Enterobacter cloacae septicaemia","volume":"64","author":"Bannon","year":"1989","journal-title":"Arch Dis Child"},{"key":"R61-6-20241212","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/INF.0b013e31823980c3","article-title":"Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis","volume":"31","author":"Watt","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R62-6-20241212","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14740338.7.5.515","article-title":"Safety of ceftriaxone sodium at extremes of age","volume":"5","author":"Monte","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"R63-6-20241212","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1128\/AAC.21.4.683","article-title":"Pharmacokinetics of cefotaxime in newborn infants","volume":"4","author":"McCracken","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"R64-6-20241212","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/AAC.23.2.341","article-title":"Ceftriaxone pharmacokinetics in newborn infants","volume":"23","author":"McCracken","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"R65-6-20241212","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jac\/13.5.471","article-title":"Pharmacokinetics of cefotaxime in neonates","volume":"13","author":"Baird-Lambert","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"R66-6-20241212","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-3476(89)80573-6","article-title":"Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates","volume":"114","author":"Kearns","year":"1989","journal-title":"J Pediatr"},{"key":"R67-6-20241212","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2165\/00003088-199222040-00004","article-title":"Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval","volume":"22","author":"Kearns","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"R68-6-20241212","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1128\/AAC.23.2.191","article-title":"Pharmacokinetics of ceftriaxone in pediatric patients with meningitis","volume":"23","author":"Steele","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"R69-6-20241212","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/14.suppl_B.161","article-title":"Pharmacokinetics and clinical evaluation of cefotaxime in children suffering with purulent meningitis","volume":"14","author":"B\u00e9gu\u00e9","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"R70-6-20241212","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1128\/AAC.28.1.149","article-title":"Pharmacokinetic evaluation of cefoperazone in infants","volume":"28","author":"Varghese","year":"1985","journal-title":"Antimicrob Agents Chemother"},{"key":"R71-6-20241212","first-page":"439","article-title":"Ceftazidime pharmacokinetics in preterm infants: Effect of postnatal age and postnatal exposure to indomethacin","volume":"40","author":"van den Anker","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"R72-6-20241212","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/0009-9236(95)90021-7","article-title":"Ceftazidime pharmacokinetics in preterm infants: Effects of renal function and gestational age","volume":"58","author":"van den Anker","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R73-6-20241212","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.33.4.498","article-title":"Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels","volume":"33","author":"Fung-Tomc","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R74-6-20241212","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.annfar.2011.07.008","article-title":"Intraventricular colistin use in neonatal meningitis caused by Acinetobacter baumanii","volume":"30","author":"Alaoui","year":"2011","journal-title":"Ann Fr Anesth Reanim"},{"key":"R75-6-20241212","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ppul.22750","article-title":"Colistin inhalation monotherapy for ventilator-associated pneumonia of Acinetobacter baumannii in prematurity","volume":"49","author":"Kang","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"R76-6-20241212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","article-title":"Framework for optimisation of the clinical use of colistin and polymyxin B: The Prato polymyxin consensus","volume":"15","author":"Nation","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201745030-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:02:19Z","timestamp":1751497339000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/evaluation-of-evidence-for-pharmacokinetics-pharmacodynamics-based-dose-optimization-of-antimicrobials-for-treating-gram-negative-infections-in-neonates\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_723_15","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}